Serina Therapeutics, Inc.
SERAMEXHealthcare● Active
$1.90
+$0.02(+1.06%)
Market Cap$20583333
P/E Ratio—
52W High$7.92
52W Low$1.22
Serina Therapeutics, Inc. (SER) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · SER · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.00B | ($0.00B) | $0.00B | $0.00B | ($0.00B) |
| Gross Margin %(computed) | — | -246.43% | 97.15% | 100.00% | -9.64% |
| Operating Expenses | |||||
| R&D Expenses | $0.01B | $0.01B | $0.00B | $0.00B | $0.00B |
| G&A Expenses | $0.01B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.02B | $0.02B | $0.01B | $0.00B | $0.00B |
| Operating Income | ($0.02B) | ($0.02B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Operating Margin %(computed) | — | — | -99.24% | -454.07% | -47.09% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.02B) | ($0.01B) | $0.01B | ($0.00B) | ($0.00B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.02B) | ($0.01B) | $0.01B | ($0.00B) | ($0.00B) |
| Net Margin %(computed) | — | — | 167.11% | -536.42% | -36.50% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.91 | $-1.51 | $0.63 | $-2.49 | $-0.59 |
| Wtd Avg Shares | 0.01B | 0.01B | 0.01B | 0.00B | 0.00B |
| EBITDA | ($0.02B) | ($0.01B) | $0.01B | ($0.00B) | ($0.00B) |
| EBITDA Margin %(computed) | — | — | 187.66% | -520.99% | -35.45% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more Serina Therapeutics, Inc. data
About Serina Therapeutics, Inc. (SER) Income Statement
Serina Therapeutics, Inc. (SER) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, SER reported revenue of $0.00B, gross profit of $0.00B (gross margin —), and net income of ($0.02B) — a net profit margin of —.
Frequently asked questions
SER · 4 questionsSerina Therapeutics, Inc. (SER) reported revenue of $0.00B for 2025, down 100.0% year-over-year.
SER revenueSER salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09